SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Accelerated Pharma, Inc. – ‘10-Q’ for 9/30/19 – ‘EX-101.CAL’

On:  Wednesday, 4/22/20, at 12:44pm ET   ·   For:  9/30/19   ·   Accession #:  1493152-20-6905   ·   File #:  333-227916

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/22/20  Accelerated Pharma, Inc.          10-Q        9/30/19   39:1.6M                                   M2 Compliance/FA

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    191K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     17K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     17K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     15K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     15K 
23: R1          Document and Entity Information                     HTML     44K 
36: R2          Condensed Consolidated Balance Sheets               HTML     83K 
29: R3          Condensed Consolidated Balance Sheets               HTML     39K 
                (Parenthetical)                                                  
15: R4          Condensed Consolidated Statements of Operations     HTML     54K 
                and Comprehensive Loss (Unaudited)                               
24: R5          Condensed Consolidated Statements of Changes in     HTML     60K 
                Stockholders' Deficiency (Unaudited)                             
37: R6          Condensed Consolidated Statements of Cash Flows     HTML     72K 
                (Unaudited)                                                      
30: R7          Business                                            HTML     21K 
14: R8          Going Concern and Management's Liquidity Plans      HTML     21K 
26: R9          Significant Accounting Policies                     HTML     36K 
19: R10         Out-of-Period Adjustment                            HTML     18K 
17: R11         Convertible Debt                                    HTML     21K 
27: R12         Notes Payable - Related Party                       HTML     16K 
38: R13         Stockholders' Equity                                HTML     18K 
20: R14         Subsequent Events                                   HTML     20K 
18: R15         Significant Accounting Policies (Policies)          HTML     58K 
28: R16         Significant Accounting Policies (Tables)            HTML     27K 
39: R17         Business (Details Narrative)                        HTML     15K 
22: R18         Going Concern and Management's Liquidity Plans      HTML     27K 
                (Details Narrative)                                              
16: R19         Significant Accounting Policies - Schedule of       HTML     18K 
                Foreign Currency Translation Exchange Rate                       
                (Details)                                                        
31: R20         Significant Accounting Policies - Schedule of       HTML     25K 
                Potentially Dilutive Securities Excluded from                    
                Computation of Net Loss Per Share (Details)                      
34: R21         Out-of-Period Adjustment (Details Narrative)        HTML     38K 
25: R22         Convertible Debt (Details Narrative)                HTML     39K 
13: R23         Notes Payable - Related Party (Details Narrative)   HTML     19K 
32: R24         Stockholders' Equity (Details Narrative)            HTML     28K 
35: R25         Subsequent Events (Details Narrative)               HTML     48K 
21: XML         IDEA XML File -- Filing Summary                      XML     61K 
33: EXCEL       IDEA Workbook of Financial Reports                  XLSX     32K 
 6: EX-101.INS  XBRL Instance -- accp-20190930                       XML    379K 
 8: EX-101.CAL  XBRL Calculations -- accp-20190930_cal               XML     79K 
 9: EX-101.DEF  XBRL Definitions -- accp-20190930_def                XML    241K 
10: EX-101.LAB  XBRL Labels -- accp-20190930_lab                     XML    352K 
11: EX-101.PRE  XBRL Presentations -- accp-20190930_pre              XML    319K 
 7: EX-101.SCH  XBRL Schema -- accp-20190930                         XSD     66K 
12: ZIP         XBRL Zipped Folder -- 0001493152-20-006905-xbrl      Zip     47K

‘EX-101.CAL’   —   XBRL Calculations — accp-20190930_cal

This Exhibit is an XBRL XML File.

                                                                                                                                                                                
<?xml version="1.0" standalone="no" encoding="windows-1252"?>
<!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.3a -->
<!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
<!-- Field: Doc-Info; Name: Source; Value: ACCP 20190930 10Q Q3 DFN.xfr; Date: 2020%2D04%2D22T16:15:37Z -->
<!-- Field: Doc-Info; Name: Status; Value: 0x800B0000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://apipharmaceuticals.com/role/DocumentAndEntityInformation" xlink:href="accp-20190930.xsd#DocumentAndEntityInformation" xlink:type="simple"/>
<link:roleRef roleURI="http://apipharmaceuticals.com/role/BalanceSheets" xlink:href="accp-20190930.xsd#BalanceSheets" xlink:type="simple"/>
<link:roleRef roleURI="http://apipharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:href="accp-20190930.xsd#BalanceSheetsParenthetical" xlink:type="simple"/>
<link:roleRef roleURI="http://apipharmaceuticals.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="accp-20190930.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
<link:roleRef roleURI="http://apipharmaceuticals.com/role/StatementsOfChangesInStockholdersDeficiency" xlink:href="accp-20190930.xsd#StatementsOfChangesInStockholdersDeficiency" xlink:type="simple"/>
<link:roleRef roleURI="http://apipharmaceuticals.com/role/StatementsOfCashFlows" xlink:href="accp-20190930.xsd#StatementsOfCashFlows" xlink:type="simple"/>
<link:roleRef roleURI="http://apipharmaceuticals.com/role/Business" xlink:href="accp-20190930.xsd#Business" xlink:type="simple"/>
<link:roleRef roleURI="http://apipharmaceuticals.com/role/GoingConcernAndManagementsLiquidityPlans" xlink:href="accp-20190930.xsd#GoingConcernAndManagementsLiquidityPlans" xlink:type="simple"/>
<link:roleRef roleURI="http://apipharmaceuticals.com/role/SignificantAccountingPolicies" xlink:href="accp-20190930.xsd#SignificantAccountingPolicies" xlink:type="simple"/>
<link:roleRef roleURI="http://apipharmaceuticals.com/role/Out-of-periodAdjustment" xlink:href="accp-20190930.xsd#Out-of-periodAdjustment" xlink:type="simple"/>
<link:roleRef roleURI="http://apipharmaceuticals.com/role/ConvertibleDebt" xlink:href="accp-20190930.xsd#ConvertibleDebt" xlink:type="simple"/>
<link:roleRef roleURI="http://apipharmaceuticals.com/role/NotesPayable-RelatedParty" xlink:href="accp-20190930.xsd#NotesPayable-RelatedParty" xlink:type="simple"/>
<link:roleRef roleURI="http://apipharmaceuticals.com/role/StockholdersEquity" xlink:href="accp-20190930.xsd#StockholdersEquity" xlink:type="simple"/>
<link:roleRef roleURI="http://apipharmaceuticals.com/role/SubsequentEvents" xlink:href="accp-20190930.xsd#SubsequentEvents" xlink:type="simple"/>
<link:roleRef roleURI="http://apipharmaceuticals.com/role/SignificantAccountingPoliciesPolicies" xlink:href="accp-20190930.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple"/>
<link:roleRef roleURI="http://apipharmaceuticals.com/role/SignificantAccountingPoliciesTables" xlink:href="accp-20190930.xsd#SignificantAccountingPoliciesTables" xlink:type="simple"/>
<link:roleRef roleURI="http://apipharmaceuticals.com/role/BusinessDetailsNarrative" xlink:href="accp-20190930.xsd#BusinessDetailsNarrative" xlink:type="simple"/>
<link:roleRef roleURI="http://apipharmaceuticals.com/role/GoingConcernAndManagementsLiquidityPlansDetailsNarrative" xlink:href="accp-20190930.xsd#GoingConcernAndManagementsLiquidityPlansDetailsNarrative" xlink:type="simple"/>
<link:roleRef roleURI="http://apipharmaceuticals.com/role/SignificantAccountingPolicies-ScheduleOfForeignCurrencyTranslationExchangeRateDetails" xlink:href="accp-20190930.xsd#SignificantAccountingPolicies-ScheduleOfForeignCurrencyTranslationExchangeRateDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://apipharmaceuticals.com/role/SignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfNetLossPerShareDetails" xlink:href="accp-20190930.xsd#SignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfNetLossPerShareDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://apipharmaceuticals.com/role/Out-of-periodAdjustmentDetailsNarrative" xlink:href="accp-20190930.xsd#Out-of-periodAdjustmentDetailsNarrative" xlink:type="simple"/>
<link:roleRef roleURI="http://apipharmaceuticals.com/role/ConvertibleDebtDetailsNarrative" xlink:href="accp-20190930.xsd#ConvertibleDebtDetailsNarrative" xlink:type="simple"/>
<link:roleRef roleURI="http://apipharmaceuticals.com/role/NotesPayable-RelatedPartyDetailsNarrative" xlink:href="accp-20190930.xsd#NotesPayable-RelatedPartyDetailsNarrative" xlink:type="simple"/>
<link:roleRef roleURI="http://apipharmaceuticals.com/role/StockholdersEquityDetailsNarrative" xlink:href="accp-20190930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple"/>
<link:roleRef roleURI="http://apipharmaceuticals.com/role/SubsequentEventsDetailsNarrative" xlink:href="accp-20190930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple"/>
<link:calculationLink xlink:type="extended" xlink:role="http://apipharmaceuticals.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information"/>
<link:calculationLink xlink:type="extended" xlink:role="http://apipharmaceuticals.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable"/>
<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable"/>
<link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://apipharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://apipharmaceuticals.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:type="arc" weight="1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://apipharmaceuticals.com/role/StatementsOfChangesInStockholdersDeficiency" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Deficiency (unaudited)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://apipharmaceuticals.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="accp-20190930.xsd#ACCP_IncreaseDecreaseInAccruedCompensation" xlink:label="loc_ACCPIncreaseDecreaseInAccruedCompensation"/>
<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="loc_ACCPIncreaseDecreaseInAccruedCompensation" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaapIncreaseDecreaseInInterestPayableNet"/>
<link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInterestPayableNet" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaapProceedsFromShortTermDebt"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromShortTermDebt" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" weight="1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://apipharmaceuticals.com/role/Business" xlink:title="00000007 - Disclosure - Business"/>
<link:calculationLink xlink:type="extended" xlink:role="http://apipharmaceuticals.com/role/GoingConcernAndManagementsLiquidityPlans" xlink:title="00000008 - Disclosure - Going Concern and Management&apos;s Liquidity Plans"/>
<link:calculationLink xlink:type="extended" xlink:role="http://apipharmaceuticals.com/role/SignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Significant Accounting Policies"/>
<link:calculationLink xlink:type="extended" xlink:role="http://apipharmaceuticals.com/role/Out-of-periodAdjustment" xlink:title="00000010 - Disclosure - Out-of-Period Adjustment"/>
<link:calculationLink xlink:type="extended" xlink:role="http://apipharmaceuticals.com/role/ConvertibleDebt" xlink:title="00000011 - Disclosure - Convertible Debt"/>
<link:calculationLink xlink:type="extended" xlink:role="http://apipharmaceuticals.com/role/NotesPayable-RelatedParty" xlink:title="00000012 - Disclosure - Notes Payable - Related Party"/>
<link:calculationLink xlink:type="extended" xlink:role="http://apipharmaceuticals.com/role/StockholdersEquity" xlink:title="00000013 - Disclosure - Stockholders&apos; Equity"/>
<link:calculationLink xlink:type="extended" xlink:role="http://apipharmaceuticals.com/role/SubsequentEvents" xlink:title="00000014 - Disclosure - Subsequent Events"/>
<link:calculationLink xlink:type="extended" xlink:role="http://apipharmaceuticals.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000015 - Disclosure - Significant Accounting Policies (Policies)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://apipharmaceuticals.com/role/SignificantAccountingPoliciesTables" xlink:title="00000016 - Disclosure - Significant Accounting Policies (Tables)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://apipharmaceuticals.com/role/BusinessDetailsNarrative" xlink:title="00000017 - Disclosure - Business (Details Narrative)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://apipharmaceuticals.com/role/GoingConcernAndManagementsLiquidityPlansDetailsNarrative" xlink:title="00000018 - Disclosure - Going Concern and Management&apos;s Liquidity Plans (Details Narrative)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://apipharmaceuticals.com/role/SignificantAccountingPolicies-ScheduleOfForeignCurrencyTranslationExchangeRateDetails" xlink:title="00000019 - Disclosure - Significant Accounting Policies - Schedule of Foreign Currency Translation Exchange Rate (Details)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://apipharmaceuticals.com/role/SignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfNetLossPerShareDetails" xlink:title="00000020 - Disclosure - Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Computation of Net Loss Per Share (Details)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://apipharmaceuticals.com/role/Out-of-periodAdjustmentDetailsNarrative" xlink:title="00000021 - Disclosure - Out-of-Period Adjustment (Details Narrative)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://apipharmaceuticals.com/role/ConvertibleDebtDetailsNarrative" xlink:title="00000022 - Disclosure - Convertible Debt (Details Narrative)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://apipharmaceuticals.com/role/NotesPayable-RelatedPartyDetailsNarrative" xlink:title="00000023 - Disclosure - Notes Payable - Related Party (Details Narrative)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://apipharmaceuticals.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000024 - Disclosure - Stockholders&apos; Equity (Details Narrative)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://apipharmaceuticals.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000025 - Disclosure - Subsequent Events (Details Narrative)"/>
</link:linkbase>

↑Top
Filing Submission 0001493152-20-006905   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Wed., May 1, 3:52:15.0am ET